Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875–84. https://doi.org/10.1200/JCO.2017.73.7585.

Article  PubMed  CAS  Google Scholar 

Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline. J Clin Oncol. 2016;34:3069–103. https://doi.org/10.1200/JCO.2016.67.1487.

Article  PubMed  CAS  Google Scholar 

Rasha F, Sharma M, Pruitt K. Mechanisms of endocrine therapy resistance in breast cancer. Mol Cell Endocrinol. 2021;532: 111322. https://doi.org/10.1016/j.mce.2021.111322.

Article  PubMed  CAS  Google Scholar 

Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, et al. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene. 1996;12:2315–24.

PubMed  CAS  Google Scholar 

Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, et al. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 2011;1:338–51. https://doi.org/10.1158/2159-8290.CD-11-0101.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Prado MD, Lallena MJ, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014;32:825–37. https://doi.org/10.1007/s10637-014-0120-7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hassan MA, Ates-Alagoz Z. Cyclin-dependent kinase 4/6 inhibitors against breast cancer. Mini Rev Med Chem. 2023;23:412–28. https://doi.org/10.2174/1389557522666220606095540.

Article  PubMed  CAS  Google Scholar 

Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, et al. MONARCH 1, a phase ii study of abemaciclib, a cdk4 and cdk6 inhibitor, as a single agent, in patients with refractory HR(+)/HER2(−) metastatic breast cancer. Clin Cancer Res. 2017;23:5218–24. https://doi.org/10.1158/1078-0432.CCR-17-0754.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638–46. https://doi.org/10.1200/JCO.2017.75.6155.

Article  PubMed  CAS  Google Scholar 

Zhang QY, Sun T, Yin YM, Li HP, Yan M, Tong ZS, et al. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2− advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol. 2020;12:1758835920963925. https://doi.org/10.1177/1758835920963925.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21:763–75. https://doi.org/10.1016/S1470-2045(20)30112-1.

Article  PubMed  CAS  Google Scholar 

Hurvitz SA, Martin M, Press MF, Chan D, Fernandez-Abad M, Petru E, et al. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR(+)/HER2(−) breast cancer. Clin Cancer Res. 2020;26:566–80. https://doi.org/10.1158/1078-0432.CCR-19-1425.

Article  PubMed  CAS  Google Scholar 

Hamilton E, Cortes J, Ozyilkan O, Chen SC, Petrakova K, Manikhas A, et al. nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR +, HER2− metastatic breast cancer. Breast Cancer Res Treat. 2022;195:55–64. https://doi.org/10.1007/s10549-022-06662-9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Johnston SRD, Toi M, O’Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:77–90. https://doi.org/10.1016/S1470-2045(22)00694-5.

Article  PubMed  CAS  Google Scholar 

Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35. https://doi.org/10.1016/S1470-2045(14)71159-3.

Article  PubMed  CAS  Google Scholar 

Rugo HS, Finn RS, Diéras V, Ettl J, Lipatov O, Joy AA, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174:719–29. https://doi.org/10.1007/s10549-018-05125-4.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–39. https://doi.org/10.1016/S1470-2045(15)00613-0.

Article  PubMed  CAS  Google Scholar 

Xu B, Hu X, Li W, Sun T, Shen K, Wang S, et al. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4. Eur J Cancer. 2022;175:236–45. https://doi.org/10.1016/j.ejca.2022.08.012.

Article  PubMed  CAS  Google Scholar 

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386:942–50. https://doi.org/10.1056/NEJMoa2114663.

Article  PubMed  CAS  Google Scholar 

Slamon DJ, Neven P, Chia S, Fasching PA, Laurentiis MD, Im SA, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382:514–24. https://doi.org/10.1056/NEJMoa1911149.

Article  PubMed  CAS  Google Scholar 

Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904–15. https://doi.org/10.1016/S1470-2045(18)30292-4.

Article  PubMed  CAS  Google Scholar 

Hermansyah D, Firsty NN, Alhudawy MN, Nasution RA. The combination of CDK 4/6 inhibitors plus endocrine treatment versus endocrine treatment alone in hormone-receptor (HR)-positive breast cancer: a systematic review and meta-analysis. Med Arch. 2022;76:333–42. https://doi.org/10.5455/medarh.2022.76.333-342.

Article  PubMed  PubMed Central  Google Scholar 

Liu Y, Wu J, Ji Z, Chen L, Zou J, Zheng J, et al. Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2—metastatic or advanced breast cancer patients: a network meta-analysis. BMC Cancer. 2023;23:816. https://doi.org/10.1186/s12885-023-11322-2.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Leung JH, Leung HWC, Wang SY, Huang SS, Chan ALF. Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis. Expert Opin Drug Saf. 2021;20:949–57. https://doi.org/10.1080/14740338.2021.1931116.

Article  PubMed  CAS  Google Scholar 

Schettini F, Giudici F, Giuliano M, Cristofanilli M, Arpino G, Mastro LD, et al. Overall survival of CDK4/6-inhibitor-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis. J Natl Cancer Inst. 2020;112:1089–97. https://doi.org/10.1093/jnci/djaa071.

Article  PubMed